Kornimate/medical-research-clean huggingface dataset:
a randomized control trial of sun protection interventions for operating engineers

Conditions: Skin Cancer Prevention

Summary: this is a randomized controlled trial testing the efficacy of 4 sun protection interventions--education only; education and mailed sunscreen; education and text message reminders; and education, mailed sunscreen, and text message reminders--among michigan operating engineers. pre- and post-intervention surveys will be collected to determine changes in sunscreen use and sun burning, the primary outcome variables. the investigators hypothesize that all interventions will increase sunscreen use and reduce burning and that the education-only intervention will have the least effect of the 4 interventions while the education, mailed sunscreen, and text messaging arm will have the greatest effect.

the education intervention will be provided during regularly scheduled safety training sessions, and the text messages and mailed sun screen (spf30)interventions will be offered during the summer when uv rays are at their highest. inclusion criteria are operating engineers who:1)are greater than 18 years of age; 2) are interested in enrolling in the sun protection study; 3) own a cell-phone that accepts text messages; and 4) are willing to share their phone number with the study team. based on power analysis, 256 subjects are needed to have 80% power to detect medium sized effects on primary outcomes. accounting for a 20% attrition rate, 320 subjects will be recruited. the analyses will include: a) paired t-tests to determine changes over time (from pre-intervention to post-intervention) in outcome variables (sunscreen use and burning) separately in the 4 intervention groups, b) repeated measures analysis of variance (rm-anova) to compare the changes in outcomes across the 4 groups, and c) t-tests on change scores as follow-ups to the rm-anova to determine exactly which groups differ from each other. sub-analyses will explore if particular subgroups of operating engineers (e.g., demographic, heath behavior, and job type subgroups) differ in sunscreen use and sun burning pre-and post-intervention.

Eligibility criteria:
inclusion criteria: * greater than 18 years of age * interested in enrolling in the sun protection study * owning a cell-phone that accepts text messages * willing to share their phone number with the study team

Keywords: worksite intervention sun protection intervention operating engineers
somatostatin analogues in the treatment of relapsing gh pituitary adenomas after surgery

Conditions: Acromegaly

Summary: at present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described. thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. it would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * having been seen at least once in consultation in the internal medicine, endocrinology and nutrition department of hautepierre hospital * subject operated for a pituitary adenoma at the hus between 01/01/2000 to 09/01/2021 * in whom biological confirmation of recurrence has been demonstrated * patient not having expressed his opposition, after information, to the reuse of his data for scientific research purposes. exclusion criteria: * subject having expressed opposition to participating in the study * treatment pre and / or post surgery by radiotherapy * no recurrence * no treatment with a somatostatin analogue for recurrence * subject under guardianship, curatorship or safeguard of justice

Keywords: acromegaly pituitary microadenoma pituitary macroadenoma somatostatin analogues hormonal control
controlling and lowering blood pressure with the mobiushd™

Conditions: Hypertension

Summary: to evaluate the safety and performance of the mobiushd system in subjects with resistant hypertension.

this is an open-label, multicenter, first-in-man clinical trial to be conducted inside the united states. eligible subjects with stage 2 resistant systemic arterial hypertension currently being treated with a minimum of three (3) anti-hypertensive drugs, who consent to study participation will be assigned to treatment with the mobiushd system. potential study participants will be consented and then screened at two (2) baseline visits beginning at least 30 days prior to mobiushd placement. qualified patients will undergo placement of the mobiushd under angiographic visualization, and will then be followed for 36 months.

Eligibility criteria:
inclusion criteria: * office cuff sbp ≥ 160 mmhg measured per protocol instructions (appendix iv) following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic. any combination medications will be counted per the active ingredient. (for example, zestoretic (lisinopril +hctz) equals two (2) anti-hypertensive medications) exclusion criteria: * known or clinically suspected baroreflex failure or autonomic neuropathy

Keywords: hypertension carotid sinus
global blood-brain barrier disruption and post-stroke cognitive decline

Conditions: Ischemic Stroke

Summary: the goal of this study is to gain a better understanding of why some individuals who have suffered a stroke experience post-stroke cognitive decline. specifically this study is testing whether global disruption of the blood-brain barrier detected at the time of the stroke is informative about the risk of post-stroke cognitive decline over the next 3 years.

it is well known that ischemic stroke is a risk factor for developing dementia. prior studies have shown that after a stroke, there can be a change in the trajectory of cognitive performance with acceleration of decline. the mechanism of this phenomenon has not been established. it is known that vascular changes in the brain, referred to as cerebral small vessel disease, are associated with cognitive decline and dementia. cerebral small vessel disease is readily seen on mri scans of the brain, and the larger the burden of these findings, the higher the risk of cognitive deficits. disruption of the blood-brain barrier has been implicated in the development of the changes seen on mri. acute stroke has been shown to disrupt the blood-brain barrier, even in parts of the brain not directly affect by the stroke. the investigators hypothesize that when there is diffuse blood-brain barrier disruption in response to an acute stroke it sets off a cascade of changes in the brain that lead to post-stroke cognitive decline.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke demonstrated on an mri scan that includes perfusion imaging with an exogenous contrast agent exclusion criteria: * inability to perform telephone-based cognitive assessments

Keywords: blood-brain barrier post-stroke cognitive impairment and dementia vascular cognitive impairment and dementia alzheimer's disease and related dementias stroke
jyb1907 in subjects with advanced solid tumors

Conditions: Solid Tumor

Summary: a phase i, multi-center, open-label study with dose-escalation and multiple expansion cohorts to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of jyb1907 in subjects with advanced solid tumors

dose escalation this part is meant to evaluate the safety, tolerability, pk, immunogenicity, preliminary antitumor activity, the mtd and rp2d of jyb1907 in patients with histologically or cytologically confirmed advanced solid tumors. expansion cohort the antitumor activity, safety, tolerability, pk and immunogenicity of jyb1907 will be further evaluated in other cohorts.

Eligibility criteria:
inclusion criteria: 1. able to provide written informed consent voluntarily; 2. age ≥18, male or female; 3. have at least one evaluable lesion (dose escalation) or measurable lesion; 4. expected survival ≥12 weeks； 5. eastern cooperative oncology group (ecog) performance status ≤2; exclusion criteria: 1. received within 4 weeks before the initial treatment, or scheduled during the study to receive a major surgery, live attenuated vaccines, or any anti-tumor therapy. 2. with severe tumor complications. 3. pregnant or lactating women, or positive serum pregnancy test; 4. concurrent participation in another interventional study； 5. with other diseases or clinical abnormalities assessed by the investigator as ineligible.
long-term safety and effectiveness of growth hormone with ghd, ts, crf, sga , iss and pws in children

Conditions: Growth Hormone Deficiency; Turner Syndrome; Chronic Renal Failure; Small for Gestational Age; Idiopathic Short Stature

Summary: the purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (eutropin inj./eutropin plus inj.) treatment with ghd (growth hormone deficiency), ts (turner syndrome),crf (chronic renal failure), sga (small for gestational age), and iss (idiopathic short stature).


Eligibility criteria:
inclusion criteria: * short stature children aged 2 years or more * children with ghd,ts, crf, sga or iss * written informed consent from the person, person's parent or legal guardian

Keywords: ghd ts crf sga iss pws
a follow-up of the influencing factors of dyskinesia in patients with parkinson's disease

Conditions: Parkinson Disease; Dyskinesias

Summary: parkinson' patients who have not had dyskinesia would be observed for 2 years in a multicenter prospective study with the purposes to clarify the predicting factors of dyskinesia.

parkinson' patients with daily levodopa dosage above 200mg and no dyskinesia would be recruited into the study. they would be observed for two years for analyzed the predicting factors of dyskinesia. at the baseline, demographic information, clinical information, blood sample, picture of tongure coating would be collected at the baseline. all participants were evaluated every three months for two years. the severity of motor symptoms were evaluated every 6 months.

Eligibility criteria:
inclusion criteria: - 1) patients have been clinically diagnosed with parkinson disease at the recruitment. 2) patients have received levodopa treatment with the daily dosage above 200mg. exclusion criteria: * 1) be suspicious of atypical parkinson or other parkinson syndrome. 2) have experienced dyskinesia. 3) incorporation to the investigation

Keywords: parkinson disease dyskinesia follow up
management of obstructive sleep apnea syndrome by expansion palatoplasty

Conditions: Obstructive Sleep Apnea of Adult

Summary: the study will be conducted to evaluate the outcome of expansion palatoplasty in management of osas.

expansion palatopladty will be conducted on patients with obstructive sleep apnea patients to evaluate the outcome.

Eligibility criteria:
inclusion criteria: * adult patients. * body mass index \< 30 kg/m2 (weight /height in m2) * mild to moderate osas * sagittal collapse of the lateral pharyngeal walls proved by drug induced sleep endoscopy (dise). exclusion criteria: * • refusing enrollment into the study. * pregnant women. * refusing the surgery * contraindication to anaesthesia * patients with multilevel of obstruction. * serious psychiatric, neurological and cardiopulmonary (copd or corpulmonale) diseases. * uncorrected hypothyroidism. * severe osas. * craniofacial anamolies. * central\& mixed apnea * morbid obesity.
18f-mfbg cardiac imaging for heart failure administration

Conditions: Rest Gated Myocardial Perfusion Imaging in Heart Failure

Summary: the clinical feasibility of 18f-fmbg cardiac pet imaging will be observed in sympathetic nervous system activity in patients with heart failure, predicted cardiac events, guided icd implantation, and evaluated therapy efficiency.

this is a prospective, single-center clinical study, using18f-meta-fluorobenzylguanidine (18f-mfbg) cardiac pet imaging to present the sympathetic nerve status in heart failure, including icd implantation. through follow-up, we analyze the correlation between the distribution of the tracer in the heart and the functions and progression of the patients, including the occurrence of ventricular arrhythmias and sudden cardiac death, and further investigate the guiding value of 18f-mfbg cardiac sympathetic nerve imaging in the screening of icd implantation patients, including primary and secondary prevention, reducing the cost of icd implantation and related complications. furthermore, to evaluate the therapy efficacy for these patients with heart failure using 18f-mfbg cardiac imaging has been considered.

Eligibility criteria:
inclusion criteria: * 1. clinically confirmed patient with chronic heart failure, lvef ≤ 40%, cardiac function nyha 2-3 grade, survival period greater than 1 year, evaluated by the heart failure center of sichuan provincial people's hospital. * 2. chronic heart failure patients were evaluated by the cardiology department of sichuan provincial people's hospital 5-10 days before icd implantation. * 3. all patients above have signed an informed consent form. exclusion criteria: * 1. heart failure, heart function nyha levels ⅰor ⅳ. * 2. the patient has already implanted icd or crt. * 3. heart transplant patients. * 4. patients with malignant tumors. * 5. heart valve disease. * 6. myocardial infarction occurred within the past three months. * 7. the patient has contraindications for icd implantation surgery. * 8. the patient does not cooperate or is unwilling to conduct the study.
rest: reducing end-of-life symptoms with touch

Conditions: Neoplasms; Pain

Summary: the purpose of this study is to determine whether massage therapy is effective in reducing pain and distress and improving quality of life among cancer patients at life's end.

relieving physical and emotional symptoms is a key component of end-of-life care. despite care, terminally ill patients are still significantly burdened by unrelieved symptoms. therapies that have potential to alleviate these symptoms deserve thorough investigation. this study will last 3 weeks. participants in this study will be randomly assigned to receive six sessions of either moving or nonmoving touch therapy, in addition to usual hospice care, for 2 weeks. moving touch therapy consists of massage therapy in which a trained therapist continually touches a person's body. the nonmoving touch therapy will be conducted by volunteers who have no previous experience in massage. participants in this group will have a volunteer rub specific body parts for 3-minute intervals. because current evidence suggests that thoughts of healing may influence the effectiveness of touch therapy, volunteers in the nonmoving therapy group will distract their minds to avoid thinking of healing processes. in both groups, the person administering the touch therapy will note all interruptions during a session, including talk, music, and television. interviews about medication use, pain, and quality of life will be used to assess participants; these interviews will be conducted at study start, immediately before and after each therapy session, and at weeks 1, 2, and 3.

Eligibility criteria:
inclusion criteria: * advanced cancer, with at least moderate pain 1 week prior to study entry * life expectancy of at least 3 weeks * able to speak english exclusion criteria: * massage therapy within 1 month prior to study entry * current use of anticoagulants * platelet count less than 10,000 * unstable spine that would interfere with touch therapy

Keywords: massage palliative care hospices cancer
analysis of urogenital injuries in polytraumatized patients

Conditions: Polytrauma

Summary: urogenital injuries occur in approximately 5-10 % of all severly injured patients. the literature lacks a thorough investigation into the mechanisms of trauma, the analysis of the whole urogenital tract and especially the correlation of thoracic and lumbar spine and pelvic injuries with urogenital injuries. the goal of this study is to provide a thorough investigation into these primary end points in a multicenter study of university hospitals in germany.


Eligibility criteria:
inclusion criteria: * iss (injury severity score) \> 15 points * patient age \> 16 * fracture of the thoracic and/ or lumbar spine * fracture of the pelvic girdle * at least one ais (abbreviated injury scale) \> 2 exclusion criteria: * iss \< 16 points * no fractures of the thoracic or lumbar spine or fractures of the pelvic girdle * no ais \> 2 * patient age under 16 years of age
predicting pain response to transcranial direct current stimulation for phantom limb pain in limb amputees

Conditions: Phantom Limb Pain

Summary: this study explores the effects transcranial direct current stimulation (tdcs, soterix ©) on phantom limb pain for patients experiencing chronic phantom limb pain in open-label study design.


Eligibility criteria:
inclusion criteria: 1. able to provide informed consent to participate in the study. 2. subject is older than 18 years. 3. 3 months of phantom limb pain (experienced regularly for at least once a week) after the amputated limb has completely healed. 4. average pain of at least 4 on a numeric rating scale in the previous week (nrs; ranging from 0 to 10). 5. if the subject is taking any medications, dosages must be stable for at least 2 weeks prior to the enrollment of the study. exclusion criteria: 1. pregnancy or trying to become pregnant in the next 2 months. 2. history of alcohol or drug abuse within the past 6 months as self-reported. 3. presence of the following contraindication to transcranial direct current stimulation ferromagnetic metal in the head (e.g., plates or pins, bullets, shrapnel) implanted head electronic medical devices (e.g., cochlear implants) 4. head injury resulting in loss of consciousness for at least 30 min or pos-traumatic amnesia for greater than 24 hours, as self-reported 5. unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues, heart failure or chronic obstructive pulmonary disease). 6. uncontrolled epilepsy 7. suffering from severe depression (as defined by a score of \>30 in the beck depression inventory).\* 8. history of unexplained fainting spells or loss of consciousness as self-reported during the last 2 years. 9. history of neurosurgery, as self-reported.

Keywords: maladaptive plasticity limb amputation phantom limb pain tdcs non-invasive brain stimulation
the effect of a neurodynamic treatment on nerve conduction in clients with low back pain

Conditions: Low Back Pain

Summary: the purpose of this study is to determine if a certain treatment for low back pain can change the way nerves in the leg send messages. specifically, the investigators will examine whether a particular type of physical therapy treatment for individuals with low back pain (neurodynamic techniques) changes the speed that nerves send/receive signals to/from the leg, as compared to a different physical therapy treatment.


Eligibility criteria:
inclusion criteria: * males and females aged 18 years and older * participants who can speak english and read, understand, and fill out the consent form and questionnaires * participants will have a certain level of low back pain graded numerically, with or without radiation to the leg * clinical decision (by same individual) as safe to participate in study based on subjective history and objective examination. exclusion criteria: * an inability to tolerate sitting for 10 minutes * nerve conduction disorders diagnosed by a physician such as, diabetes or ms * current participant in an investigational drug study (within past 3 months)

Keywords: nerve conduction h-reflex, mobilizations with neurodynamic component
treatment for completers of the study b7a-mc-mbcm

Conditions: Diabetic Retinopathy

Summary: to provide ruboxistaurin treatment to patients who completed the b7a-mc-mbcm study (nct00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. patients must be off study drug for 6 to 18 months from completion of b7a-mc-mbcm before beginning b7a-mc-mbdv. additional data will be gathered to determine the long-term safety and effect of ruboxistaurin on vision.


Eligibility criteria:
inclusion criteria: * patients that completed month 36 (visit 15) of the study b7a-mc-mbcm, and the investigator believes he/she would benefit from ruboxistaurin treatment. exclusion criteria: * patients that discontinued from the study b7a-mc-mbcm and/or the investigator does not believe he/she would benefit from ruboxistaurin treatment.
the hienome study: genome sequencing for perinatal hie

Conditions: Hypoxic Ischemic Encephalopathy of Newborn; Hypoxic Ischemic Encephalopathy; Hypoxic Ischemic Encephalopathy (HIE)

Summary: perinatal hypoxic-ischemic encephalopathy is a rare severe condition in which neonates present with encephalopathy and a clinical history suggestive of prenatal or perinatal hypoxic-ischemic injury. emerging evidence suggests that genetic conditions are frequently identified in cases of perinatal hie; however, it is unclear which neonates with this diagnosis warrant genetic testing. this study will offer clinical genome sequencing to neonates with hie who are undergoing total body cooling (therapeutic hypothermia) and their parents.


Eligibility criteria:
inclusion criteria: * delivery ≥35w0d gestation * diagnosed with moderate or severe hie, or hie with seizures * undergoing total body cooling / therapeutic hypothermia * able to provide blood or buccal samples during birth hospitalization * admitted to texas children's hospital main, west, or woodlands nicu exclusion criteria: * parents/family not willing to allow participation * inability to collect sufficient neonatal blood samples (in some circumstances, a buccal swab may be used as backup)

Keywords: hypoxic-ischemic encephalopathy genetic testing genome sequencing
carer involvement in exercises for people with acquired brain injury.

Conditions: Acquired Brain Injury (Including Stroke)

Summary: increasing the amount of exercises completed has been shown to help recovery for people after a brain injury. this study will explore if providing extra training of exercises prescribed to a patient and carer team, will allow more practice of these exercises, better abilities to move and balance, and to assess if carer confidence changes with doing this. it is a repeated case design in the in-patient acute neurosciences setting at the norfolk and norwich university hospital nhs trust (nnuh).


Eligibility criteria:
inclusion * adults with acquired brain injury on nnuh neurosciences unit with a carer physically able to complete exercises with the patient. * patient to be able to follow simple commands (1 stage) for exercise intervention. * patient able to consent along with their relative together to participation in the study. exclusion: * discharge plan for esd from initial assessment with no care package required due to too short timeframe of being an acute in-patient. * patient's with severe cognitive - communication deficits meaning they cannot follow 1 stage command for exercises or consent to the study. * severe pain, joint abnormality or spasticity limiting participation in exercise programme. * carer/relative not able to physically help the patient with the required exercises or carer/relative not able to consent to the study.

Keywords: stoke acquired brain injury rehabilitation exercise therapy